An Anti-CD22-
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
21
01
2020
revised:
07
07
2020
accepted:
09
11
2020
pubmed:
5
12
2020
medline:
21
10
2021
entrez:
4
12
2020
Statut:
ppublish
Résumé
We are interested in developing a second generation of antibody-drug conjugates (ADCs) for the treatment of non-Hodgkin lymphoma (NHL) that could provide a longer duration of response and be more effective in indolent NHL than the microtubule-inhibiting ADCs pinatuzumab vedotin [anti-CD22-vc-monomethyl auristatin E (MMAE)] and polatuzumab vedotin (anti-CD79b-vc-MMAE). Pinatuzumab vedotin (anti-CD22-vc-MMAE) and polatuzumab vedotin (anti-CD79b-vc-MMAE) are ADCs that contain the microtubule inhibitor MMAE. Clinical trial data suggest that these ADCs have promising efficacy for the treatment of NHL; however, some patients do not respond or become resistant to the ADCs. We tested an anti-CD22 ADC with a
Identifiants
pubmed: 33273056
pii: 1535-7163.MCT-20-0046
doi: 10.1158/1535-7163.MCT-20-0046
doi:
Substances chimiques
Aminobenzoates
0
CD22 protein, human
0
Immunoconjugates
0
Oligopeptides
0
Sialic Acid Binding Ig-like Lectin 2
0
auristatin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
340-346Informations de copyright
©2020 American Association for Cancer Research.
Références
Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6:e254–65.
Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to Brentuximab Vedotin. Mol Cancer Ther. 2015;14:1376–84.
Yu S-F, Zheng B, Go MA, Lau J, Spencer S, Raab H, et al. A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin based ADCs. Clin Cancer Res. 2015;21:3298–306.
Su D, Chen J, Cosino E, Cruz-Chuh Dela J, Davis H, Del Rosario G, et al. Antibody-drug conjugates derived from cytotoxic seco-CBI-dimer payloads are highly efficacious in xenograft models and form protein adducts in vivo. Bioconjug Chem. 2019;30:1356–70.
Su D, Kozak KR, Sadowsky J, Yu S-F, Fourie-O'Donohue A, Nelson C, et al. Modulating antibody-drug conjugate payload metabolism by conjugation site and linker modification. Bioconjug Chem. 2018;29:1155–67.
Li D, Poon KA, Yu S-F, Dere R, Go M, Lau J, et al. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-hodgkin lymphoma. Mol Cancer Ther. 2013;12:1255–65.
Pinheiro J, Bates D, DebRoy S, et al. nlme: linear and nonlinear mixed effects models. R package.
Li D, Lee D, Dere RC, Zheng B, Yu S-F, Fuh FK, et al. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin. Br J Pharmacol. 2019;176:3805–18.
Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, Grimbacher B, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol. 2012;188:497–503.
Vallerskog T, Heimbürger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006;8:R167.
Fuh FK, Looney C, Li D, Poon KA, Dere RC, Danilenko DM, et al. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells. Br J Pharmacol. 2017;174:628–40.
Giddens AC, Lee HH, Lu G-L, Miller CK, Guo J, Lewis Phillips GD, et al. Analogues of DNA minor groove cross-linking agents incorporating aminoCBI, an amino derivative of the duocarmycins: synthesis, cytotoxicity, and potential as payloads for antibody-drug conjugates. Bioorg Med Chem. 2016;24:6075–81.
Fu Y, Ho M. DNA damaging agent-based antibody-drug conjugates for cancer therapy. Antib Ther. 2018;1:33–43.
Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Acquired resistance to antibody-drug conjugates. Cancers. 2019;11:394.